Image Credit: Shutterstock Here’s a shocking statistic: in 2020, 7.6% of the world’s population was living with the most common form of arthritis – osteoarthritis (OA). That amounts to 595 million people globally and 32.5 million adults in the U.S. That’s a lot of people with painful knees, hips, and other joints. Although pain medication … Continue reading Gene Therapy for Osteoarthritis Shows Positive Results in Early Trial
FDA
FDA Grants RMAT Designation to Luxa Biotechnology’s CIRM-funded Dry AMD Therapy
Credit: Shutterstock The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for a project focused on vision loss that was funded in part by the California Institute for Regenerative Medicine (CIRM). This designation is given to highly promising regenerative medicine therapies that treat serious or life-threatening diseases with the goal of accelerating the path … Continue reading FDA Grants RMAT Designation to Luxa Biotechnology’s CIRM-funded Dry AMD Therapy
A Step Forward in the Fight Against Advanced Kidney Cancer
Photo Courtesy: Allogene Therapeutics Metastatic renal cell carcinoma (RCC) is an advanced form of kidney cancer with few treatment options and a five-year survival rate of less than 17%. With funding support from CIRM, Allogene Therapeutics is developing ALLO-316, an allogeneic CAR-T cell therapy which targets CD70—a protein highly expressed on clear cell renal cell … Continue reading A Step Forward in the Fight Against Advanced Kidney Cancer
Two CIRM-funded research projects receive RMAT designation from FDA
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to two research projects funded by the California Institute for Regenerative Medicine (CIRM). RMAT is a fast-track designation that can help speed up the development, review, and potential approval of treatments for serious or life-threatening diseases. The first RMAT designation … Continue reading Two CIRM-funded research projects receive RMAT designation from FDA
Why diversity in clinical trials is essential
The California Institute for Regenerative Medicine (CIRM) is proud to join fellow advocates of clinical trial diversity in applauding a new law that will allow the U.S. Food & Drug Administration (FDA) to require diverse representation in clinical trials. A clinical trial, as defined by the FDA, tests potential treatments in human volunteers to see … Continue reading Why diversity in clinical trials is essential
Making transplants easier for kids, and charting a new approach to fighting solid tumors.
Every year California performs around 100 kidney transplants in children but, on average, around 50 of these patients will have their body reject the transplant. These children then have to undergo regular dialysis while waiting for a new organ. Even the successful transplants require a lifetime of immunosuppression medications. These medications can prevent rejection but … Continue reading Making transplants easier for kids, and charting a new approach to fighting solid tumors.
A timeless message about stem cells
Dr. Daniel Kota The world of stem cell research is advancing rapidly, with new findings and discoveries seemingly every week. And yet some things that we knew years ago are still every bit as relevant today as they were then. Take for example a TEDx talk by Dr. Daniel Kota, a stem cell researcher and … Continue reading A timeless message about stem cells
Sweet 16 and counting for stem cell clinical trial
Dr. Judy Shizuru: Photo courtesy Jasper Therapeutics Over the years the California Institute for Regenerative Medicine (CIRM) has invested a lot in helping children born with severe combined immunodeficiency (SCID), a fatal immune disorder. And we have seen great results with some researchers reporting a 95 percent success rate in curing these children. Now there’s … Continue reading Sweet 16 and counting for stem cell clinical trial
Fast Track Designation for a therapy making transplants safer for children with a fatal immune disorder
Bone marrow transplant For children born with severe combined immunodeficiency (SCID) life can be very challenging. SCID means they have no functioning immune system, so even a simple infection can prove life threatening. Left untreated, children with SCID often die in the first few years of life. There are stem cell/gene therapies funded by the … Continue reading Fast Track Designation for a therapy making transplants safer for children with a fatal immune disorder
How stem cells helped Veronica fight retinitis pigmentosa and regain her vision
Veronica and Elliott Growing up Veronica McDougall thought everyone saw the world the way she did; blurry, slightly out-of-focus and with tunnel vision. As she got older her sight got worse and even the strongest prescription glasses didn’t help. When she was 15 her brother tried teaching her to drive. One night she got into … Continue reading How stem cells helped Veronica fight retinitis pigmentosa and regain her vision
The Stem Cellar 